Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Pancreatic cancer, particularly pancreatic ductal adenocarcinoma, exhibits aggressive growth and invasiveness.
• Cyclin D1 is a key regulator of cell cycle progression and has been implicated in various cancers, including pancreatic cancer.

Purpose of the Study:

• To investigate the biological effects of cyclin D1 gene silencing in pancreatic cancer cells.
• To evaluate the therapeutic potential of lentivirus-mediated shRNA targeting cyclin D1 in preclinical models of pancreatic cancer.

Main Methods:

• Utilized a replication-defective lentivirus system delivering small hairpin RNA (shRNA) to target and silence cyclin D1 expression.
• Assessed the impact of cyclin D1 silencing on pancreatic cancer cell lines (ASPC-1 and BxPC3) in vitro, measuring cell growth and invasiveness.
• Administered intratumoral injections of the recombinant lentivirus into pre-existing tumors in vivo to evaluate its effect on tumor growth, proliferation, and angiogenesis.

Main Results:

• Cyclin D1 silencing led to significant reductions in cyclin D1 protein levels in pancreatic cancer cell lines.
• In vitro studies showed decreased cell growth and invasiveness following cyclin D1 knockdown.
• Intratumoral delivery of lentivirus targeting cyclin D1 attenuated tumor growth, reduced proliferation and angiogenesis, and decreased vascular endothelial growth factor (VEGF) expression in vivo.

Conclusions:

• Lentivirus-delivered shRNA targeting cyclin D1 effectively suppresses the growth, invasiveness, and tumorigenicity of human pancreatic cancer cells.
• The observed reduction in pro-angiogenic potential, indicated by decreased VEGF expression, further supports the therapeutic implications.
• Intratumoral administration of cyclin D1-targeting viruses presents a promising novel therapeutic strategy for pancreatic ductal adenocarcinoma.